Over recent decades, researchers have made significant progress in many cancer types but advances in pancreatic cancer have been frustratingly limited. That is why the results presented in Chicago at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting generated so much excitement throughout the oncology community. Anna Berkenblit, MD, MMSc, Chief Scientific & Medical Officer of the Pancreatic Cancer Action Network described the findings by stating, “The results presented at the ASCO meeting for daraxonrasib were jaw-dropping and represent the most significant advance we have ever seen in pancreatic cancer.” 13
Dr. Berkenblit is not alone in this assessment, as many experts have called the findings the most significant breakthroughs in pancreatic cancer treatment in years.¹˒²
At the center of this breakthrough is a new investigational targeted therapy called daraxonrasib (RMC-6236), an oral medication designed to block cancer-driving RAS/KRAS signaling pathways that are responsible for the vast majority of pancreatic cancers.¹˒³
Exciting Data
An estimated 90-95% of pancreatic ductal adenocarcinomas (PDAC), the most common sub-type of pancreatic cancer, contain KRAS or related RAS mutations. It is these mutations that help drive tumor growth. For years, these mutations were considered nearly impossible to target effectively with medication.¹˒²
Clinical trial results suggest that Daraxonrasib may change that.
In the international Phase III RASolute 302 clinical trial, patients with previously treated metastatic pancreatic cancer who received daraxonrasib lived a median of 13.2 months compared with 6.6–6.7 months for patients receiving standard chemotherapy, representing an approximately 60% reduction in the risk of death. The treatment also improved progression-free survival, quality of life, and symptom control. “Simply put, of the 500 patients who participated in the RASolute 302 trial, those treated with Daraxonrasib on average lived nearly twice as long and demonstrated an improved quality of life compared to chemotherapy!”, Shruti Singh, MD, Director of Clinical Research at Northwest Cancer Centers. ¹˒²˒⁵˒¹²
This data was so impressive that when it was presented at the ASCO plenary session, it received a standing ovation from the thousands of Oncologists and medical professionals present.
Real World Considerations
With all this excitement surrounding Daraxonrasib in the medical community, the real-world questions of “What exactly is Daraxonrasib?”, “What does this mean for me?” and “How can I access this new treatment?” are being asked across the country by the estimated 100,000 Americans battling pancreatic cancer.
What exactly is daraxonrasib?
Daraxonrasib is a targeted therapy known as a RAS(ON) multi-selective inhibitor. It is a pill taken once daily by mouth. Unlike traditional chemotherapy, which attacks rapidly dividing cells throughout the body, daraxonrasib is designed to specifically target and interrupt the signaling pathways that drive pancreatic cancer growth.¹˒³ “This targeted approach not only contributes to the medication’s effectiveness, but it is also the primary reason for the reported better quality of life and reduced side effects when compared to chemotherapy”, said Singh.
What does this mean to patients?
The documented benefits to patients as presented during the ASCO plenary session are numerous. They include, longer survival¹˒⁴˒¹², better control of disease progression¹˒⁴˒¹², delayed worsening of symptoms and pain⁵, improved quality of life¹˒⁵˒¹², and in some situations, an alternative to additional intravenous chemotherapy. ¹˒⁵
Is daraxonrasib approved by the FDA?
YES! Over the past several months, patients and providers alike anxiously waited for daraxonrasib to be approved for them. Yesterday, August 26, 2026, the FDA approved Daraxonrasib under the brand name Rasonque.
How Can a patient receive daraxonrasib (Rasonque)?
Physicians at Northwest Cancer Centers are now prescribing this breakthrough treatment and arranging for the patient to receive the medication from one of the specialty pharmacies selected by Revolution Medicine to coordinate distribution in the first several months following approval.
It should be noted that while the medication is in a different class, patients receiving this treatment require oncology office visits, labs, and follow-up similar to patients on chemotherapy or immunotherapy regimens. Working with a provider experienced and prepared to use this new treatment should be a consideration when choosing their oncologist.
For providers, preparing for a treatment like daraxonrasib involves far more than simply prescribing a new medication. It requires expertise in molecular testing to identify eligible patients, experience managing complex oral targeted therapies, coordination with specialty pharmacies, patient financial assistance resources, and familiarity with the pharmacy distribution system and clinical trial pathways.
As the era of KRAS-targeted treatment in pancreatic cancer begins, over the past several months, Northwest Cancer Centers worked to ensure that patients in Northwest Indiana will not have to travel to benefit from the latest advances in cancer care.
Read how NCC is working to expand daraxonrasib access, molecular testing, patient support services, and targeted therapy management for patients throughout Northwest Indiana and the Midwest. A Breakthrough in Pancreatic Cancer Care: How Northwest Cancer Centers Has Prepared for the Era of KRAS-targeted Treatment
References